Table 2.
Summary of current recruiting clinical trials for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) found on clinicaltrials.gov and World Health Organization (WHO) database.
| Vaccine Platform | Antigen | Administration Method | Country | Trial Phase | Main Primary Outcome Measures | Estimated Study Completion Date/Results |
|---|---|---|---|---|---|---|
| BCG | Non-SARS-CoV-2 | I.D | Australia (n = 4170) |
Phase III (NCT04327206) |
COVID-19 disease incidence including symptoms and a positive SARS-CoV-2 PCR test | 30 March 2022 |
| BCG | Non-SARS-CoV-2 | I.D. | Netherlands (n = 1500) |
Phase III (NCT04328441) |
Healthcare workers absenteeism | 25 December 2020 |
| BCG | Non-SARS-CoV-2 | I.D. | South Africa (n =5500) |
Phase III, (NCT04379336) | Healthcare workers morbidity and mortality | 28 April 2021 |
| BCG | Non-SARS-CoV-2 | I.D | US (n = 1800) |
Phase IV, (NCT04348370) | Healthcare workers, reduction in infection and disease severity | November 2021 |
| Antigen presenting cells | Cons. epi | S.C | China (n = 100) |
Phase I (NCT04299724) |
Frequency of adverse events and serious adverse events and proportion of subjects with positive T cell response | 31 December 2024 |
| Lentiviral vector system | Cons. epi | S.C and I.V | China (n = 100) |
Phase I/II (NCT04276896) |
Clinical improvement based on the seven-point scale Lower Murray lung injury score |
31 December 2024 |
| Adenovirus Vector System | FL-S | I.M | China (n = 108) |
Phase I (NCT04313127) Phase II (NCT04341389) |
Adverse events and immunogenicity | Mild to moderate transient adverse events in 81% of participant. B and T cell response in all participant. Pre-existing Ad immunity diminished vaccine response |
| Adenovirus Vector System | FL-S | I.M for comparator, n.m for vaccine | UK (n = 510) |
Phase I/II (NCT04324606) |
Number of virologically confirmed symptomatic cases and safety | May 2021 |
| mRNA | FL-S | I.M | US (n = 105) |
Phase I (NCT04283461) |
Safety and reactogenicity | 20 September 2021 |
| mRNA | n.m | I.M | US (n = 7600) |
Phase I/II (NCT04368728) |
Local reactions and systemic events | 27 January 2023 |
| DNA | S | I.D. and E.P | US (n = 40) |
Phase I (NCT04336410) |
Adverse events and immunogenicity | April 2021 |
| Inactivated vaccine | Whole virion | n.m | China (n = 744/422) |
Phase I/II (NCT04352608/NCT04383574) |
Adverse events and immunogenicity | 13 December 2020 |
| Inactivated vaccine | Whole virion | n.m | China | Phase I/II (ChiCTR2000032459) |
Adverse events and immunogenicity | __ |
| Inactivated vaccine | Whole virion | n.m | China | Phase I/II (ChiCTR2000031809) |
Adverse events and immunogenicity | __ |
| Inactivated vaccine | Whole virion | n.m | China (n = 942) |
Phase I/II NCT04412538 |
Adverse events and immunogenicity | __ |
| Protein subunit | rS nano | I.M | Australia (n = 131) |
Phase I (NCT04368988) |
Adverse events and immunogenicity | 31 July 2021 |
I.M = Intramuscular, I.D = Intradermal, S.C = Subcutaneous, I.V = Intravenous, E.P =Electroporation, n.m = not mentioned, FL = Full-Length, Cons. Epi = conserved epitopes in structural and protease genes, S = spike, nano = nanoparticle, BCG = Bacillus Calmette–Guérin, COVID-19 = Coronavirus disease 2019.